首页> 美国卫生研究院文献>Biointerphases >Surface modification of a polyhedral oligomeric silsesquioxanepoly(carbonate-urea) urethane (POSS-PCU) nanocomposite polymer as a stent coating forenhanced capture of endothelial progenitor cells
【2h】

Surface modification of a polyhedral oligomeric silsesquioxanepoly(carbonate-urea) urethane (POSS-PCU) nanocomposite polymer as a stent coating forenhanced capture of endothelial progenitor cells

机译:多面体低聚倍半硅氧烷的表面改性聚(碳酸脲)聚氨酯(POSS-PCU)纳米复合材料作为支架涂层增强内皮祖细胞的捕获

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

An unmet need exists for the development of next-generation multifunctional nanocomposite materials for biomedical applications, particularly in the field of cardiovascular regenerative biology. Herein, we describe the preparation and characterization of a novel polyhedral oligomeric silsesquioxane poly(carbonate-urea) urethane (POSS-PCU) nanocomposite polymer with covalently attached anti-CD34 antibodies to enhance capture of circulating endothelial progenitor cells (EPC). This material may be used as a new coating for bare metal stents used after balloon angioplasty to improve re-endothelialization. Biophysical characterization techniques were used to assess POSS-PCU and its subsequent functionalization with anti-CD34 antibodies. Results indicated successful covalent attachment of anti-CD34 antibodies on the surface of POSS-PCU leading to an increased propensity for EPC capture, whilst maintaining in vitro biocompatibility and hemocompatibility. POSS-PCU has already been used in 3 first-in-man studies, as a bypass graft, lacrimal duct and a bioartificial trachea. We therefore postulate that its superior biocompatibility and unique biophysical properties would render it an ideal candidate for coating medical devices, with stents as a prime example. Taken together, anti-CD34 functionalized POSS-PCU could form the basis of a nano-inspired polymer platform for the next generation stent coatings.
机译:对于用于生物医学应用的下一代多功能纳米复合材料的开发存在未满足的需求,特别是在心血管再生生物学领域。在这里,我们描述了新型多面体低聚倍半硅氧烷聚(碳酸脲)聚氨酯(POSS-PCU)纳米复合聚合物的制备和表征,该聚合物具有共价连接的抗CD34抗体以增强对循环内皮祖细胞(EPC)的捕获。这种材料可以用作裸金属支架的新涂层,用于在球囊血管成形术后使用以改善再内皮化。使用生物物理表征技术评估POSS-PCU及其随后用抗CD34抗体的功能。结果表明,抗CD34抗体成功共价附着在POSS-PCU表面上,导致EPC捕获的倾向增加,同时保持了体外生物相容性和血液相容性。 POSS-PCU已在3项首次人体研究中用作旁路移植物,泪道和生物人工气管。因此,我们假设其出色的生物相容性和独特的生物物理特性将使其成为涂覆医疗器械的理想候选者,而支架就是一个很好的例子。综上所述,抗CD34功能化的POSS-PCU可以构成下一代支架涂层的纳米启发聚合物平台的基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号